Mercachem logo voor websites



It is our great pleasure to announce today thatMercachemSyncom has acquired Alcami’s European cGMP CMC drug substance development site, based in Weert, the Netherlands. The acquisition will allow us to support larger scale clinical active pharmaceutical ingredient (API) requirements, alongside current capabilities in Prague, as well as bringing state-of-the-art solid-state research capabilities. The long experience of the Weert team in designing and driving early clinical drug substance development programs will complement extensive process research capabilities based in Groningen and Nijmegen. 

The full press release regarding this acquisition can be viewed through the button below.

Full press release   

Contact us